Telix Pharmaceuticals Future Growth
Future criteria checks 6/6
Telix Pharmaceuticals is forecast to grow earnings and revenue by 38.3% and 20.1% per annum respectively. EPS is expected to grow by 37.9% per annum. Return on equity is forecast to be 33.7% in 3 years.
Key information
38.3%
Earnings growth rate
37.9%
EPS growth rate
| Biotechs earnings growth | 35.3% |
| Revenue growth rate | 20.1% |
| Future return on equity | 33.7% |
| Analyst coverage | Good |
| Last updated | 27 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,318 | 179 | 192 | 193 | 8 |
| 12/31/2025 | 985 | 86 | 123 | 120 | 9 |
| 12/31/2024 | 766 | 55 | 76 | 75 | 9 |
| 6/30/2024 | 646 | 49 | 25 | 50 | N/A |
| 3/31/2024 | 576 | 32 | 11 | 27 | N/A |
| 12/31/2023 | 503 | 5 | 13 | 24 | N/A |
| 9/30/2023 | 430 | -21 | 7 | 17 | N/A |
| 6/30/2023 | 357 | -48 | 2 | 10 | N/A |
| 3/31/2023 | 249 | -77 | -42 | -31 | N/A |
| 12/31/2022 | 160 | -104 | -78 | -64 | N/A |
| 9/30/2022 | 94 | -111 | -89 | -77 | N/A |
| 6/30/2022 | 29 | -119 | -101 | -91 | N/A |
| 3/31/2022 | 18 | -100 | -81 | -75 | N/A |
| 12/31/2021 | 8 | -81 | -61 | -59 | N/A |
| 9/30/2021 | 7 | -70 | -35 | -34 | N/A |
| 6/30/2021 | 7 | -59 | -9 | -8 | N/A |
| 3/31/2021 | 6 | -52 | -4 | -3 | N/A |
| 12/31/2020 | 5 | -45 | 2 | 2 | N/A |
| 9/30/2020 | 4 | -40 | -13 | -12 | N/A |
| 6/30/2020 | 3 | -36 | -27 | -27 | N/A |
| 3/31/2020 | 3 | -32 | -26 | -25 | N/A |
| 12/31/2019 | 3 | -28 | -24 | -23 | N/A |
| 9/30/2019 | 3 | -23 | -26 | -26 | N/A |
| 6/30/2019 | 2 | -19 | -29 | -29 | N/A |
| 3/31/2019 | 1 | -16 | -25 | -25 | N/A |
| 12/31/2018 | 0 | -14 | -21 | -21 | N/A |
| 9/30/2018 | 0 | -12 | -16 | -16 | N/A |
| 6/30/2018 | N/A | -10 | -11 | -11 | N/A |
| 3/31/2018 | N/A | -8 | N/A | -9 | N/A |
| 12/31/2017 | N/A | -6 | N/A | -6 | N/A |
| 12/31/2016 | N/A | 0 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: T3X's forecast earnings growth (38.3% per year) is above the savings rate (0.8%).
Earnings vs Market: T3X's earnings (38.3% per year) are forecast to grow faster than the German market (20% per year).
High Growth Earnings: T3X's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: T3X's revenue (20.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: T3X's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: T3X's Return on Equity is forecast to be high in 3 years time (33.7%)